Special Issue: Clinical Utility of Non-coding RNAs, a Next-Generation Class of Biomarkers
Published 28 September, 2017
Advances in the understanding of the molecular role of non-coding RNAs (ncRNAs) in both physiological and pathological conditions have significantly contributed to the identification of alternative molecular pathways which have started to influence the planning of secondary prevention strategies and the selection of new therapeutic modalities for human diseases. In oncology, dysregulation of ncRNA significantly affects cancer initiation, progression, metastasis and therapeutic responsiveness. Intracellular and extracellular ncRNA’s plays a crucial role in cancer progression and therapy. Various bioactive dietary molecules have been regulating ncRNA’s through different mechanisms including epigenetic modifications. Next step will be the definitive introduction of ncRNAs’ world into clinical practice.
Hence, the main topics of this issue are:
- Non-coding RNAs as biomarker for cancer progression and metastasis
- Regulation of non-coding RNAs on chemoresistance and therapy
- Non-coding RNAs regulations by bioactive diets
- Dietary non-coding RNAs in cancer prevention and therapy
- Epigenetic regulation of non-coding RNAs in cancer
- The clinical impact of non-coding RNAs testing
This special issue will include reviews, original research articles, perspective in ncRNA research into clinical practice.
Paper submission due:
31 October, 2018
Special Issue Guest Editors:
Matteo Fassan
Department of Medicine (DIMED)
Surgical Pathology and Cytopathology Unit
University of Padua, Padua,
Italy
Email: matteo.fassan@unipd.it
Syed Musthapa Meeran
Laboratory of Cancer Epigenetics
Division of Endocrinology
CSIR-Central Drug Research Institute
Lucknow, India
Email: s.musthapa@cftri.res.in